March 22, 2019

Dr. Stuart Altman, Chair  Sen. Cindy Friedman, Chair  Rep. Jennifer Benson, Chair
Massachusetts Health Policy Committee on Health Care Committee on Health Care
Commission  Financing  Financing
50 Milk Street, 8th Floor  Massachusetts State House  Massachusetts State House
Boston, MA 02109  Boston, MA 02133  Boston, MA 02133

Dear Dr. Altman, Senator Friedman and Representative Benson:

Re: State Cost Growth Benchmark

Thank you for the opportunity to offer comments as the Health Policy Commission considers adjusting the cost growth benchmark for 2020. The current 3.1% cost growth benchmark was set through a process established in Chapter 224 of the Acts of 2012 and the Commission has outlined a number of factors that may be considered when deciding whether an adjustment to the benchmark is warranted. These factors include:

1. Massachusetts’ performance to date
2. Impact of enrollment and demographic changes on performance
3. Financial impact of modifying the benchmark
4. Significant changes to the state or federal health care landscape
5. Role of the benchmark in HPC’s statutory responsibilities
6. Feedback from market participants and interested parties

When reviewing Massachusetts’ performance to date, the cost growth benchmark has been exceeded in two of the past four years for which final figures are available. Initial figures for 2016-17 show an increase of 1.6%, well below the benchmark of 3.6%. When looking at different components of THCE, and within that, the major categories of commercial spending, there remains wide variation in levels of growth.

While we do not advocate THCE be disaggregated and the benchmark be separately applied to each component, it is instructive to see what factors have contributed to THCE growth falling beneath or above the benchmark since passage of Ch. 224.

<table>
<thead>
<tr>
<th>Components of THCE</th>
<th>Change 2016 - 17</th>
<th>Growth vs. Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial</td>
<td>3.1%</td>
<td>▼</td>
</tr>
<tr>
<td>Prescription Drugs</td>
<td>4.1%</td>
<td>▲</td>
</tr>
<tr>
<td>Hospital Inpatient</td>
<td>1.0%</td>
<td>▼</td>
</tr>
<tr>
<td>Hospital Outpatient</td>
<td>4.9%</td>
<td>▲</td>
</tr>
<tr>
<td>Physician Services</td>
<td>1.5%</td>
<td>▼</td>
</tr>
<tr>
<td>MassHealth</td>
<td>-1.1%</td>
<td>▼</td>
</tr>
<tr>
<td>Medicare</td>
<td>3.2%</td>
<td>▼</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2.8%</strong></td>
<td>▼</td>
</tr>
</tbody>
</table>
The differences in the growth rates for different components of THCE illustrate how performance in one area can be offset by growth in the others, and how many of the cost drivers are beyond the direct control of the different sectors. For example, taxes and assessments imposed by the Affordable Care Act, the rising per capita cost of commercial health insurance, and the cost of new drugs and innovative medical devices are all significant cost drivers, but are largely beyond the direct control of hospitals, payers and state government.

Hospital inpatient spending fell below the benchmark last year, while hospital outpatient spending was above the benchmark. Hospitals have made considerable progress in slowing rates of cost growth, through greater operating efficiencies and adoption of new models of care delivery and payment. Noticeably, the rate of spending growth for both hospital inpatient and outpatient services decreased by 1.8% and 0.7% respectively from 2016 – 2017. Yet there are still factors that are largely beyond the direct control of hospital leaders.

The cost pressures hospitals face are intense and, in many cases, beyond the complete control of hospitals. As the chart to the right indicates, nearly 60% of hospital costs are labor costs. This portion of hospital spending is subject to inflationary pressure as workers expect cost of living adjustments to at least keep pace with inflation.

In addition to typical inflationary pressures on labor costs, a number of actions taken at the federal level in 2018 – 2019 are all ready posing financial difficulties for hospitals. Changes to the Medicare Outpatient Prospective Payment System (OPPS) set to take effect in 2019 are slated to dramatically reduce reimbursement for services provided to Medicare beneficiaries in hospital outpatient departments. The 2018 finalized OPPS rule also includes a nearly 30% reduction in reimbursement to hospitals for pharmaceutical purchases made under the 340B program. Taken together, these policy changes will contribute mightily to the financial stress facing many hospitals in Massachusetts and will create additional inflationary pressure on the cost of hospital operations.

Another area where hospitals have limited ability to impact cost growth is in the area of pharmaceutical spending. As the Commission and Center for Health Information Analysis have documented, growth in prescription drug spending has far outpaced inflation and the cost growth benchmark in recent years. A significant portion of overall costs in hospitals - particularly academic medical centers and specialty hospitals - is the result of prescription drug prices.

Lastly, an important factor the HPC should consider when setting the cost growth benchmark is significant uncertainty at the federal level as it relates to health policy. As Congress and the Trump Administration continue efforts to undermine the Affordable Care Act, consider additional major changes to Medicaid funding and the 340B drug pricing program, there will be significant consequences both locally and nationally. The next several years will bring continuing uncertainly to healthcare in the United States.
COBTH supports maintaining the cost growth benchmark at its current 3.1%, but cautions the Commission to be mindful of the many factors outside the control of providers, payers and the Commonwealth that may make meeting this target difficult.

Regardless of where the benchmark is set, our member hospitals are committed to continuing the hard work of reducing cost growth during times of intense upward pressure on costs and significant uncertainty at the federal level. We are also committed to working with the Commission and our partners in the healthcare sector on initiatives aimed at addressing those cost drivers that are not within in our direct control.

Sincerely,

Alec Lebovitz
Government & Community Affairs Specialist
Conference of Boston Teaching Hospitals